“The BluePath team was phenomenal in supporting our late lifecycle product that required new evidence to demonstrate the affordability of our product versus a new biosimilar launching. They developed a simple, yet accurate budget impact model that allowed us to demonstrate the financial benefits without impacting clinical outcomes. Within a single quarter, the team at BluePath working alongside with us, had an economic model developed that ultimately helped assist in delaying uptake of the new generic. The timely turnaround and near-term impact on delaying uptake with key customers were a clear and quantifiable return on investment. Thank you BluePath for your support.”

“BPS delivered! Our team needed a unique economic model focused primarily on outcomes that are not monetized, but external stakeholders were unfamiliar with the disease area. The team at BluePath conceptualized a visual-based economic model that animated the patient journey linking the clinical trial endpoints to relevant stakeholder outcomes and presented the entire model on a digital platform. Although we needed an accurate and credible economic model, the approach to data presentation was the key to our success. Presenting the model as an animation with educational materials and an audio guide for users raised the bar for our expectations of a robust economic model.”

“We had an urgent request from market access on a recent ICER evaluation and it required an analysis and response within 24 hours. BluePath was able to support the analysis and provide the evidence based to support our response. There are always willing to go above and beyond and understand the daily stresses and uncertainty faced.”